Across TCGA pan-cancer cohorts, SRIP1 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of SRIP1’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SRIP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SRIP1 is over-expressed in tumor.
KIRC are the cancer types where SRIP1 tumor–normal differential expression is most reproducible.